Alphatec Holdings, Inc. (NASDAQ:ATEC) Short Interest Up 20.1% in July

Alphatec Holdings, Inc. (NASDAQ:ATECGet Rating) saw a significant growth in short interest in July. As of July 15th, there was short interest totalling 5,730,000 shares, a growth of 20.1% from the June 30th total of 4,770,000 shares. Approximately 9.4% of the company’s stock are short sold. Based on an average daily volume of 763,300 shares, the short-interest ratio is currently 7.5 days.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on ATEC shares. Lake Street Capital restated a “buy” rating and set a $9.00 target price on shares of Alphatec in a report on Friday, July 15th. HC Wainwright raised their target price on Alphatec from $19.00 to $20.00 in a report on Friday, May 6th. Finally, Needham & Company LLC cut their target price on Alphatec from $15.00 to $13.00 and set a “buy” rating on the stock in a report on Thursday, May 26th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Alphatec has an average rating of “Moderate Buy” and a consensus target price of $17.50.

Insider Activity

In other news, major shareholder Paul Segal acquired 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 14th. The stock was acquired at an average cost of $6.95 per share, for a total transaction of $347,500.00. Following the completion of the acquisition, the insider now owns 288,825 shares in the company, valued at $2,007,333.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, major shareholder Paul Segal acquired 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 14th. The stock was acquired at an average cost of $6.95 per share, for a total transaction of $347,500.00. Following the completion of the acquisition, the insider now owns 288,825 shares in the company, valued at $2,007,333.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Patrick Miles sold 100,000 shares of the stock in a transaction on Wednesday, May 18th. The stock was sold at an average price of $8.34, for a total value of $834,000.00. Following the sale, the chief executive officer now owns 5,858,634 shares of the company’s stock, valued at $48,861,007.56. The disclosure for this sale can be found here. Over the last quarter, insiders acquired 79,700 shares of company stock worth $563,300 and sold 300,000 shares worth $2,339,500. Corporate insiders own 33.93% of the company’s stock.

Institutional Investors Weigh In On Alphatec

A number of institutional investors have recently added to or reduced their stakes in the company. Arizona State Retirement System grew its position in Alphatec by 8.0% during the second quarter. Arizona State Retirement System now owns 18,836 shares of the medical technology company’s stock worth $123,000 after buying an additional 1,390 shares in the last quarter. TownSquare Capital LLC grew its position in Alphatec by 3.1% during the first quarter. TownSquare Capital LLC now owns 53,827 shares of the medical technology company’s stock worth $619,000 after buying an additional 1,609 shares in the last quarter. Russell Investments Group Ltd. grew its position in Alphatec by 6.3% during the second quarter. Russell Investments Group Ltd. now owns 36,411 shares of the medical technology company’s stock worth $237,000 after buying an additional 2,152 shares in the last quarter. BNP Paribas Arbitrage SA grew its position in Alphatec by 17.4% during the fourth quarter. BNP Paribas Arbitrage SA now owns 15,218 shares of the medical technology company’s stock worth $174,000 after buying an additional 2,259 shares in the last quarter. Finally, Cullen Frost Bankers Inc. grew its position in Alphatec by 4.5% during the fourth quarter. Cullen Frost Bankers Inc. now owns 55,365 shares of the medical technology company’s stock worth $633,000 after buying an additional 2,385 shares in the last quarter. 53.52% of the stock is owned by institutional investors and hedge funds.

Alphatec Stock Down 1.5 %

Shares of NASDAQ:ATEC opened at $7.43 on Tuesday. The stock’s 50-day moving average is $7.09 and its 200-day moving average is $9.41. Alphatec has a 52-week low of $5.73 and a 52-week high of $15.34. The company has a quick ratio of 1.76, a current ratio of 2.62 and a debt-to-equity ratio of 7.78.

Alphatec (NASDAQ:ATECGet Rating) last issued its quarterly earnings results on Thursday, May 5th. The medical technology company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.14). The business had revenue of $70.93 million during the quarter, compared to analyst estimates of $67.72 million. Alphatec had a negative net margin of 60.83% and a negative return on equity of 147.10%. On average, sell-side analysts forecast that Alphatec will post -1.4 earnings per share for the current fiscal year.

Alphatec Company Profile

(Get Rating)

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement.

See Also

Want More Great Investing Ideas?

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.